Emerging biomolecules for practical theranostics of liver hepatocellular carcinoma

Miner Hu; Xiaojun Xia; Lichao Chen; Yunpeng Jin; Zhenhua Hu; Shudong Xia; Xudong Yao

doi:10.1016/j.aohep.2023.101137

Emerging biomolecules for practical theranostics of liver hepatocellular carcinoma

Ann Hepatol. 2023 Jul 13;28(6):101137. doi: 10.1016/j.aohep.2023.101137. Online ahead of print.

Authors

Miner Hu¹, Xiaojun Xia¹, Lichao Chen¹, Yunpeng Jin¹, Zhenhua Hu², Shudong Xia³, Xudong Yao⁴

Affiliations

¹ International Institutes of Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang, China.
² International Institutes of Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang, China; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, Zhejiang, China. Electronic address: huzhenh@zju.edu.cn.
³ International Institutes of Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang, China. Electronic address: shystone@126.com.
⁴ International Institutes of Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang, China. Electronic address: 0617555@zju.edu.cn.

PMID: 37451515
DOI: 10.1016/j.aohep.2023.101137

Abstract

Most cases of hepatocellular carcinoma (HCC) are able to be diagnosed through regular surveillance in an identifiable patient population with chronic hepatitis B or cirrhosis. Nevertheless, 50% of global cases might present incidentally owing to symptomatic advanced-stage HCC after worsening of liver dysfunction. A systematic search based on PUBMED was performed to identify relevant outcomes, covering newer surveillance modalities including secretory proteins, DNA methylation, miRNAs, and genome sequencing analysis which proposed molecular expression signatures as ideal tools in the early-stage HCC detection. In the face of low accuracy without harmonization on the analytical approaches and data interpretation for liquid biopsy, a more accurate incidence of HCC will be unveiled by using deep machine learning system and multiplex immunohistochemistry analysis. A combination of molecular-secretory biomarkers, high-definition imaging and bedside clinical indexes in a surveillance setting offers a comprehensive range of HCC potential indicators. In addition, the sequential use of numerous lines of systemic anti-HCC therapies will simultaneously benefit more patients in survival. This review provides an overview on the most recent developments in HCC theranostic platform.

Keywords: Deep learning; Hepatocellular carcinoma diagnosis; Liquid biopsy; Systemic therapies.

Publication types

Review